Table 3 Univariate and multivariate analyses of clinicopathological parameters and TACC3 expression for Disease-free survival (n = 264)

Age (< 37 vs. ≥ 37 years)

0.530 (0.266–1.056)

Figo stage (I vs. II vs. III vs. IV)

1.941 (1.330–2.832)

1.055 (0.690–1.614)

Tumor size (cm) (< 4.5 vs. ≥ 4.5)

2.303 (1.280–4.145)

1.138 (0.581–2.228)

Histological type (HPVA vs. NHPVA)

0.310 (0.162–0.592)

0.536 (0.241–1.192)

Differentiation (Well vs. Moderate vs. Poor)

1.266 (0.778–2.062)

Stromal invasion (< 1/3 vs.1/3–2/3 vs. ≥ 2/3)

2.363 (1.557–3.585)

1.468 (0.908–2.373)

Nerve invasion (Negative vs. Positive)

2.846 (1.426–5.680)

0.659 (0.275–1.581)

LVI (None vs. Focal vs. Moderate vs. Extensive)

1.600 (1.214–2.108)

1.367 (0.975–1.917)

LNM (Negative vs. Positive)

4.631 (2.685–7.987)

2.665 (1.350–5.262)

Parametrium invasion (Negative vs. Positive)

4.099 (1.987–8.456)

1.495 (0.635–3.523)

Surgical margin (Negative vs. Positive)

2.687 (1.264–5.712)

1.019 (0.435–2.390)

HPV subtype (HPV 16 vs. HPV18 vs. Other types vs. Not available vs. Negative)

0.846 (0.637–1.123)

MMR (dMMR vs. pMMR)

0.969 (0.350–2.686)

P16 (Negative vs. Positive)

0.335 (0.172–0.652)

0.669 (0.293–1.530)

Ki67 (< 12.5vs. ≥ 12.5)

0.784 (0.431–1.426)

TACC3 (Low vs. High)

2.621 (1.517–4.530)

2.265 (1.232–4.166)